Executive summary
Targeted Osmotic Lysis (TOL) is an emerging, non-invasive therapeutic approach designed to treat advanced carcinomas by exploiting the physiological differences between malignant and healthy cells. The protocol combines the cardiac glycoside digoxin with a pulsed electric field (PEF) to induce selective lysis in cancer cells. Advanced cancers often over-express voltage-gated sodium channels (VGSCs) and Na+/K+-ATPase (sodium pumps) at levels ten to fifty times higher than normal tissue. TOL leverages that over-expression to flood cancer cells with sodium and water, producing osmotic rupture while sparing healthy cells.
Preclinical data and veterinary case series have shown tumor regression, increased survival, and improved quality of life in companion animals. Recent human pilot studies and case reports indicate similar success in metastatic breast cancer, malignant melanoma, and cutaneous squamous cell carcinoma. While not yet FDA-approved, TOL represents a shift toward targeted, non-toxic cancer care that avoids the pain, scarring, and tissue destruction associated with conventional chemotherapy and radiation.
Mechanism of Targeted Osmotic Lysis
Highly malignant cells show dysregulated expression of ion channels to facilitate invasion and metastasis. The treatment process is a two-step synergistic protocol.
1. Pharmacological blockade
Digoxin is administered to a steady-state therapeutic concentration, typically 0.5 to 2.0 ng/ml. Digoxin inhibits the Na+/K+ ATPase sodium pump, preventing the cell from extruding sodium.
2. Electric field stimulation
The patient is exposed to a uniform low-power coaxial pulsed electric field. The field opens the over-expressed VGSCs, allowing massive sodium influx into the cancer cell.
The osmotic event
Intracellular hypernatremia creates an osmotic gradient that draws water into the cell. Because the sodium pumps are blocked, the cell cannot restore ionic balance. Internal pressure exceeds membrane capacity. The cell lyses.
Why the targeting is selective
Healthy non-excitable cells express few sodium channels. Advanced carcinomas use over-expressed VGSCs to power migration, invasion, and invadopodia formation. The density differential makes malignant cells uniquely susceptible to the osmotic overload that TOL induces.
The role of digoxin in oncology
Digoxin, traditionally a medication for heart failure and atrial fibrillation, has moved to the forefront of TOL research and broader oncology.
Standard pharmacology
- Source. Derived from the foxglove plant (Digitalis lanata).
- Cardiac mechanism. Increases myocardial contractility by inhibiting the Na+/K+ ATPase pump.
- Pharmacokinetics. Half-life of approximately 36 hours. Primarily excreted unchanged by the kidneys.
- Narrow therapeutic index. Requires careful monitoring to avoid toxicity, which can cause arrhythmias, nausea, and visual disturbances.
Oncology-specific insights
- CTC cluster dissolution. A 2025 proof-of-concept trial in metastatic breast cancer patients found that digoxin treatment at 0.7 to 1.4 ng/ml reduced the size of circulating tumor cell (CTC) clusters. Mechanistically, digoxin downregulates cell-cell adhesion and cell-cycle-related genes.
- TOL synergy. In the TOL protocol, digoxin is the agent that "traps" sodium within the malignant cell.
- Augmentation with imiquimod. In some cutaneous cancer cases, imiquimod is used as a pretreatment. It releases inflammatory mediators (TNFα, prostaglandins) that further increase VGSC expression, potentially enhancing TOL effectiveness.
Clinical evidence: veterinary milestones
TOL has been safety-tested in over forty companion animals under veterinary supervision.
| Patient | Diagnosis | Outcome (per published case report) |
|---|---|---|
| Marley (Labrador) |
Nasal carcinoma | Large tumor disappeared. 17-month follow-up showed no evidence of cancer. Lived 3 years post-treatment. |
| Dodge (English Shepherd) |
Lung cancer | Treated for 7.5 months. Necropsy later revealed the tumor was 90 percent necrotic. |
| Otto (Rottweiler) |
Bladder cancer | Survived 9+ months despite a 2-3 month prognosis. Tumor size was reduced. |
| Gizmo (Maltese mix) |
Facial carcinoma | 15-20 percent tumor reduction over six treatments. |
Clinical evidence: human case studies and pilot trials
Malignant melanoma (Case SS)
A 51-year-old male with Stage 3 melanoma (level IV invasion) underwent three cycles of TOL. Post-treatment MRI and dermatologic evaluation confirmed complete resolution of the primary lesion with no residual scarring or evidence of metastasis at the published follow-up window.
Squamous cell carcinoma (Case DP)
A 66-year-old male with multiple facial SCCs achieved complete resolution of palpable tumors. Post-treatment biopsies revealed normal skin morphology and a near-total absence of VGSC-overexpressing cells.
Cervical SCC emergency use
A 46-year-old female with aggressive stage IIB cervical squamous cell carcinoma, ECOG performance status 4, who had exhausted cisplatin, paclitaxel, carboplatin, bevacizumab, and pembrolizumab, received TOL under emergency-use protocol. CT showed tumor density reduction from 70 to 47 Hounsfield units by day 21. The patient survived nine weeks post-treatment, significantly exceeding the two-week prognosis. Published in Current Oncology 2021. Full reference: /literature.
Metastatic breast cancer study
A 2025 trial of nine metastatic breast cancer patients met its primary endpoint with a statistically significant reduction in mean CTC cluster size of negative 2.2 cells per cluster following digoxin administration.
Treatment protocol and patient experience
Screening and eligibility
Patients undergo a thorough review of medical records, biopsy results, and immunohistofluorescence (IHF) analysis to confirm the tumor over-expresses VGSCs.
Standard human protocol
- Digoxin loading. Daily oral doses for 5 to 7 days prior to treatment to reach steady-state blood levels.
- Cycles. Two days of therapy per week for three weeks per cycle.
- Procedure. The patient lies in a coaxial ring device (similar in form to a CT scanner) for approximately 120 minutes per session. The field is whole-body, allowing it to target undetected micrometastases.
Observed side effects
- During stimulation, some patients report warmth, tingling, or a "pins and needles" sensation in the area of the tumor.
- Erythema and serous fluid leakage from visible lesions often occur as the tumor begins to lyse.
- TOL does not produce the systemic toxicity, hair loss, or severe nausea associated with chemotherapy.
Where the procedure is currently available
The procedure is currently offered at international partner clinics operating under their local regulatory framework.
- Mexico. CORE Medical, Tijuana. Under COFEPRIS oversight. coremedical.mx
- Honduras. Roatan partner clinic.
- Australia. Partner sites operating under the TGA Special Access Scheme.
- United States. Access is limited to authorized clinical trials, expanded access (21 CFR 312 Subpart I), and the Right to Try Act of 2018.
Conclusion and outlook
- Safety. Clinical observations in humans and animals indicate that TOL is well-tolerated and does not damage normal tissue in the published case experience.
- Efficacy signal. Tumor regression and first-in-human proof of principle have been established in the published literature for several carcinoma types.
- Quality of life. Unlike surgery or radiation, TOL allows rapid re-epithelialization without disfiguring scars.
- Current status. Available today in Roatan (Honduras), Tijuana (Mexico), and Australia under local regulatory framework. Investigational in the United States. FDA-pathway toxicology and clinical work is ongoing.
References and further reading
The complete catalogue of peer-reviewed publications underpinning the briefing above is at /literature. Full procedure detail is at the sister-site companion page fixcancer.org/procedure.